SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SharonAI Holdings, Inc. is a technology company. It focuses on high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings (SHAZ) is surging amidst community discussion following the release of an ambitious long-term roadmap outlining significant capacity expansion into 2028, further fueled by its association with the bullish AI sector and a notable photo of its co-founder with NVIDIA's CEO.

MKS, Inc. provides instruments, systems, subsystems and process control solutions to measure, control, power, monitor, and analyze parameters of manufacturing processes to improve process performance and productivity for its customers. It operates through the following segments: VSD (Vacuum Solutions Division), PSD (Photonics Solutions Division), and MSD (Materials Solutions Division). The VSD segment delivers foundational technology solutions to semiconductor manufacturing, electronics and packaging and specialty industrial applications. The PSD Segment provides a range of instruments, components and subsystems to edge semiconductor manufacturing, electronics and packaging and specialty industrial applications. The MSD segment develops process and manufacturing technologies for advanced surface modification, electroless and electrolytic plating, and surface finishing. The company was founded in 1961 and is headquartered in Andover, MA.

MKS Inc.

MKS Instruments, Inc.

MKS Instruments is trending as investors digest a mixed earnings report, where an EPS miss was overshadowed by strong revenue growth and optimistic guidance, reinforcing its position as a key enabler in the expanding AI and semiconductor capital equipment sector. The community is actively discussing its significant role in data center buildout and next-generation manufacturing, viewing it as an attractive long-term play despite some technical signals suggesting caution and recent convertible note offerings.

Berachain

Berachain (BERA) is heavily discussed as its innovative Proof-of-Liquidity (PoL) model and recent ecosystem upgrades, including new vaults and integrations, fuel optimism for a significant breakout. However, the community remains divided, with strong bullish sentiment clashing with warnings about volatility and concerns over token distribution.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

Heightened community discussion around recently resurfaced Jeffrey Epstein files, which some claim expose links to Bitcoin's early funding, is driving strong bearish sentiment and calls to short the cryptocurrency via BITI. This narrative fuels widespread speculation that Bitcoin is fundamentally flawed and poised for a significant decline.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is actively discussed as its acquisition of Astria Therapeutics completes, integrating the late-stage HAE therapy navenibart into its pipeline just before upcoming earnings and new clinical data presentations. Community sentiment is mixed, balancing optimism for the strengthened rare disease portfolio against concerns over stock performance, perceived dilution, and significant short interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following robust Phase 2 axSpA clinical trial results for sonelokimab, described by the community as potentially "best-in-class" and generating significant buzz ahead of its Investor Day, amplifying discussions around substantial short interest and potential major acquisition interest.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies (EMAT) is trending with significant volatility and trading halts, fueled by its extremely low public float and widespread community discussion around its potential to secure a US-based critical minerals supply chain. Investors are actively debating short-term "pump and dump" risks versus a long-term opportunity, as the company aims to reduce reliance on China for rare earth materials.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending sharply higher after securing FDA approval for BYSANTI, a New Chemical Entity addressing Bipolar I Disorder and Schizophrenia with patent protection extending to 2044. The community is now highly focused on the stock's significant undervaluation, with widespread speculation of a major re-rating or buyout fueled by BYSANTI's market potential and the future 'mega blockbuster' prospects of its GLP-1 nausea drug candidate.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is seeing increased attention driven by the launch of its perpetuals DEX on Ethereum Mainnet, a prominent $1M trading competition, and key developments like the end of token inflation. The community is actively discussing the protocol's potential for price breakouts as it returns its core operations to Ethereum.

Fastenal Co. engages in the distribution of fasteners and tools. It also operates hardware stores. The company was founded by Robert A. Kierlin, Michael M. Gostomski, Henry K. McConnon, John D. Remick, and Stephen M. Slaggie in November 1967 and is headquartered in Winona, MN.

Fastenal Co.

Fastenal is trending following its recent earnings report, which, despite matching EPS, showed revenue falling short and highlighted persistent margin pressures in a sluggish industrial market. The community is keenly discussing these results and the implications of its announced 2-for-1 stock split.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is doubling down on its mission to revolutionize cancer treatment with radiation therapy. In just a few short weeks, the company has achieved a series of notable milestones, from a promising Phase 2 trial update to the appointment of veteran biotech executive George Scorsis as Chairman of the Board.With its lead candidate Ropidoxuridine already making waves in glioblastoma trials, Shuttle Pharma is positioning itself at the forefront of oncology innovation. The moves come as Shuttle looks to emulate recent breakthroughs by industry leaders such as <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/lantheus-holdings/">Lantheus Holdings (NASDAQ: LNTH)</a> and <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/novartis/">Novartis (NYSE: NVS)</a>, both of which have brought radiopharmaceutical therapies to market using similar underlying science.<h3>George Scorsis Steps In as Chairman</h3>On Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">Shuttle Pharma announced</a> George Scorsis as the new Chairman of its Board of Directors. Scorsis brings over 25 years of executive experience, particularly in highly regulated sectors including biotech and cannabis. His resume includes leadership roles at Liberty Health Sciences and Mettrum Health Corp., and he currently chairs both <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/awakn-life-sciences">Awakn Life Sciences (CSE: AWKN) (OTCQB: AWKNF)</a> and Entourage Health Corp.Commenting on <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">his new role</a> at Shuttle, Scorsis stated:<blockquote>I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.</blockquote>Scorsis also previously served as Chairman of <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/sol-global-investments">SOL Global Investments (CSE: SOL) (OTC: SOLCF)</a>, which further illustrates his deep involvement in pioneering healthcare ventures.His appointment reflects Shuttle’s strategic push to strengthen its leadership team as it enters a pivotal period of clinical and commercial development.<h3>Ropidoxuridine Phase 2 Trial Gains Momentum</h3>The heart of Shuttle Pharma’s pipeline is <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/therapeutics/ropidoxuridine/">Ropidoxuridine</a> (IPdR), a novel radiation sensitizer currently in Phase 2 clinical trials for the treatment of glioblastoma. The aggressive brain cancer has limited treatment options and remains incurable. Shuttle’s approach aims to amplify the efficacy of radiation therapy while keeping side effects minimal.As of <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">May 8, 2025</a>, nearly 50% of the trial’s initial enrollment target had been met. Impressively, 84% of patients enrolled had completed all seven cycles of treatment. Trial sites—ranging from Georgetown University Medical Center to the Miami Cancer Institute—reported the drug was well tolerated, with toxicity scores not exceeding 2 on a 1-5 scale.Dr. Anatoly Dritschilo, who recently stepped down as Chairman and Chief Scientific Officer, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">said</a>, “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”Patients are being randomized into two dose cohorts—1,200 mg/day and 960 mg/day—to determine the optimal regimen. Once identified, an additional 14 patients will be enrolled at the best dose to reach statistical significance. The trial aims to complete enrollment later this year, with data readouts expected in 2026.Chris Cooper, Shuttle’s interim CEO, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">commented</a>:<blockquote>With nearly 50% of patient enrollment achieved in the initial randomized portion and 84% of enrolled patients completing all seven cycles, the trial is advancing steadily at esteemed cancer centers. Ropidoxuridine has been well-tolerated and we have begun analyzing pharmacokinetic and pharmacodynamic samples to optimize dosing and response. Our goal is to complete enrollment later this year, with follow-up and data readouts anticipated in 2026.</blockquote>The U.S. FDA has granted Orphan Drug Designation to Ropidoxuridine, giving Shuttle potential marketing exclusivity if approved. Given that an estimated 800,000 U.S. cancer patients undergo radiation therapy annually—and 400,000 of those for curative purposes—Shuttle’s target market is sizable and growing.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/5-minute-deep-dive-scorecard-is-shuttle-pharmaceuticals-nasdaq-shph-ready-for-a-massive-breakout/">5-Minute Deep Dive Scorecard: Is Shuttle Pharmaceuticals (NASDAQ: SHPH) Ready for a Massive Breakout?</a><h3>Innovation Extends Beyond the Clinic</h3>On May 15, 2025, Shuttle released a <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">corporate update</a> highlighting the company’s many recent developments. In addition to clinical progress, Shuttle has made strides in the diagnostics space. The company entered a sponsored research agreement with the University of California, San Francisco (UCSF) to develop a PSMA-targeted ligand for theranostic use in prostate cancer.Furthermore, Shuttle filed a <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-targets-prostate-cancer-with-psma-ligand-breakthrough/">provisional patent</a> titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing was developed with Dr. Alan Kozikowski, a medicinal chemist whose past work helped enable the development of Lantheus’ Pylarify and Novartis’ Pluvicto—two commercially successful radiopharmaceuticals.Shuttle’s recent underwritten <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-closes-5-75-million-offering/">public offering</a> helped solidify its financial footing, with $4.5 million in cash and equivalents reported as of March 31, 2025. That cash will fund both the ongoing clinical trial and preclinical research efforts.<h3>Strengthened Leadership Amid Key Transitions</h3>While Scorsis’ arrival marks a new chapter, Shuttle has also seen notable exits. Dr. Dritschilo resigned from the Board and his role as CSO, while Michael Vander Hoek, the company’s VP of Regulatory, announced his retirement effective June 10.New board members Oleh Nabyt and Joseph Tung join Scorsis in reinforcing Shuttle’s governance and bringing expanded business and legal acumen to the table.<h3>Looking Ahead</h3>Shuttle Pharmaceuticals appears to be building momentum across multiple fronts—clinical, intellectual property, diagnostics, and leadership. With a new Chairman in place, promising mid-trial results, and a strengthened pipeline backed by a scientific pedigree, the company is drawing comparisons to past success stories, such as Lantheus Holdings and Novartis.Investors will watch closely as the Ropidoxuridine trial progresses toward full enrollment and data publication in 2026. If Shuttle can successfully deliver on its ambitions, it could play a major role in transforming radiation therapy for cancer patients worldwide.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/videos/shuttle-pharma-showcases-cancer-treatment-advancements-at-planet-microcap-vegas-2025/">This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:invest@wealthyvc.com">invest@wealthyvc.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations

George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.

According to Goldman Sachs Research, a 5% increase in the tariff rate is estimated to reduce S&amp;P 500 earnings per share by 1-2%. The recently considered tariffs have reduced Goldman Sachs' S&amp;P 500 EPS forecasts by roughly 2-3%.&nbsp; Growth stocks are beaten down as recent tariffs triggered a sharp sell-off, with all major indexes, including the Dow Jones Industrial Average (DJI), S&amp;P 500 (SPX), and NASDAQ Composite (IXIC), falling significantly. The impact of US tariffs on the stock market is significant. &nbsp;Historically, the S&amp;P 500 has fallen by 5-7% when the US announced tariffs, as seen in 2018-2019. However, history suggests the downturn was temporary as it caused disruptions, but markets rebounded after the Phase I trade deal. Despite this, like energy, US manufacturers, Biotechnology, and Financials may benefit. As we navigate the current market landscape, let’s take a closer look at 5 stocks across various industries that are not prone to tariff uncertainty and present attractive buying opportunities. Shuttle Pharmaceuticals (SHPH) Shuttle Pharmaceuticals (NASDAQ: SHPH) is a specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy. The company is developing innovative radiation sensitizers, including its lead candidate Ropidoxuridine, to enhance the effectiveness of radiation therapy and bring new treatments to patients with cancer. Phase 2 Clinical Trial for Ropidoxuridine: The company is currently conducting a Phase 2 clinical trial for Ropidoxuridine to treat glioblastoma, a deadly form of brain cancer. The trial is designed to evaluate the safety and efficacy of Ropidoxuridine in combination with radiation therapy. The company has also completed a public offering of $5.75 million to fund its Phase 2 clinical trial, marketing efforts, and general corporate expenses. &nbsp;Expanding its Pipeline: Shuttle Pharmaceuticals is also developing other oncology drug candidates, including SP-2-225 and SP-1-303, which are in the preclinical stages of development. These candidates have the potential to treat a range of cancers, including breast, lung, and prostate cancer. Building Strategic Partnerships: The company is building strategic partnerships with leading cancer centers and research institutions to advance its research and development programs.&nbsp; While Shuttle Pharmaceuticals may not be directly impacted by tariffs, the company may benefit from the Trump administration’s efforts to promote domestic pharmaceutical manufacturing and reduce reliance on foreign imports. The administration is also expected to increase funding for cancer research, which could benefit Shuttle Pharmaceuticals and other companies developing innovative cancer treatments.Kinsale Capital (KNSL) Kinsale Capital (NYSE: KNSL) is a leading excess and surplus lines insurance provider that operates various business segments, including commercial property insurance. The company has a strong presence in the US and is poised for growth, driven by its strategic initiatives and market demand. Expanding Product Lines: Kinsale is continuously expanding its product lines and has recently launched a new agribusiness underwriting unit focused on farm and ranch exposures. Disciplined Underwriting: Kinsale maintains a disciplined approach to underwriting by focusing on high-margin opportunities and managing risks effectively. The company is investing in technology to drive cost efficiencies. Increased Demand: Kinsale’s expanded product lines, strategic underwriting, and focus on high-margin opportunities will drive growth in demand for its insurance products. Strong Financial Metrics: Kinsale has a solid balance sheet, a high cash conversion rate, and a well-diversified investment portfolio that will support its growth and profitability. &nbsp;United States Steel (X) United States Steel (NYSE: X) is a major player in the steel industry, with a strong presence in the United States and a history of innovation and adaptation. The company is expected to benefit from the recent announcement by President Trump to double the tariffs on Canadian steel and aluminum to 50%. Increased Demand and Pricing Power: The company will likely have higher demand, more pricing power, and reduced competition as imports from Canada become more expensive and reduce competition, allowing it to gain market share and increase its revenue. &nbsp;Improving Asset Turnover and Margins: United States Steel is focused on optimizing its operations and improving its asset turnover, with a goal of increasing its return on capital and reducing its costs. Investing in Strategic Projects: United States Steel is investing in new projects, such as the Big River Steel mill, to increase its production capacity and improve its competitiveness. &nbsp;Partnering with Other Companies: The company is exploring partnerships with other companies, such as Nippon Steel, to share technology and expertise and improve its operations. United States Cellular (USM) United States Cellular (NYSE: USM) is a leading telecommunications company providing wireless services to customers across the United States. The company is focusing on expanding its 5G network infrastructure, particularly in rural areas, through partnerships. Upgrading its 5G Network Infrastructure: United States Cellular has partnered with Ericsson to upgrade its 5G network infrastructure in rural areas by leveraging Ericsson’s advanced cell-site router technology to provide efficient transport infrastructure for mid-band spectrum deployment.&nbsp; &nbsp;Monetizing its Spectrum Holdings: United States Cellular has recently made deals to sell select spectrum assets to AT&amp;T and other mobile network operators. The company has agreed to sell a portion of its retained spectrum licenses to AT&amp;T for $1. billion and has also reached definitive deals to monetize around 70% of its total spectrum holdings (excluding mmWave). Financial Performance and Guidance: The company reported Q4 non-GAAP EPS of $0.05 and revenue of $970 million, which beat estimates by $5.3 million. Spectrum Portfolio And Future Plans: After the proposed sales, UScellular will be left with 1.86 billion MHz-Pops of low and mid-band spectrum, as well as 17.2 billion MHz-Pops of mmWave spectrum, with the substantial majority of retained value in the C-band spectrum. Plains GP (PAGP) Plains GP (NASDAQ: PAGP) is a midstream oil and gas company with diversified operations, primarily in crude oil. The company also owns an indirect, non-economic controlling interest in Plains All American Pipeline, a Master Limited Partnership focused on oil and gas midstream operations. Expanding its Asset Base Through Bolt-On Acquisitions: Plains GP has recently completed several acquisitions, including the Ironwood Midstream Energy acquisition and the purchase of the remaining 50% interest in Midway Pipeline, to strengthen its integrated asset base. &nbsp;Increasing Quarterly Distribution: The company has announced a 20% increase in its quarterly distribution, bringing the annualized distribution to $1.52 per unit, and plans to continue increasing the dividend by at least $0.15 per year with a 160% coverage. Investing in Growth Capital Expenditure: Plains GP plans to invest around $400 million annually in growth capex, including investments in Permian JV improvements to drive growth and increase earnings. Optimizing its Assets and Operations: The company is focused on optimizing its assets and operations, including increasing utilization of Corpus Christi-bound assets and growing Permian crude production to drive growth and increase efficiency. &nbsp;Conclusion While all the companies discussed present strong growth potential, Shuttle Pharmaceuticals stands out as a unique investment opportunity. As a US-based company with a domestic supply chain, it is insulated from trade-related disruptions. Moreover, its cutting-edge approach to cancer treatment, ongoing clinical trials, and strategic partnerships position it for substantial growth in the biotech sector.&nbsp; Read Next: Why This Electric Vehicle Market Player’s Proprietary Battery-Swapping Technology is a Game-Changer Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here. Join the Discussion in the WVC Facebook Investor Group Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com. &nbsp;This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. &nbsp;Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage. In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure. <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;

In this photo illustration, the Kinsale Capital Group logo is displayed on a smartphone screen

Growth Stocks Are Beaten Down. Why It’s Temporary and What Should Be On Your Shopping List Instead

According to Goldman Sachs Research, a 5% increase in the tariff rate is estimated to reduce S&P 500 earnings per share by 1%-2%

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's valuation stands at just $4 million.<ul><li>Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness. A sensitizer is a drug designed to enhance the effectiveness of radiation by making cancer cells more susceptible to damage while sparing healthy cells. This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation. &nbsp;</li><li>Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. While several peer companies in Phase 2 trials boast market caps exceeding $500 million, Shuttle’s valuation stands at just $4 million. This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. &nbsp;</li><li>Founded by Georgetown University faculty, Shuttle Pharma is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.</li></ul>&nbsp;Shuttle Pharmaceuticals: Revolutionizing Radiation Therapy by Making it More Effective at Killing Cancer Cells while Sparing Healthy Cells<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals/">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is a clinical-stage biotech company specializing in therapies that enhance the efficacy of radiation therapy while minimizing side effects. Beyond Ropidoxuridine, Shuttle Pharma’s pipeline includes promising candidates like SP-2-225 and SP-1-303, along with diagnostic tools that could streamline FDA approval and open additional revenue streams.Dr. Anatoly Dritschilo, the company’s CEO, brings decades of experience as a radiation oncology leader and professor at Georgetown University. His tenure at the institution has cemented his reputation as an innovator in radiosensitization and therapeutic resistance strategies.&nbsp;Hope for Those Facing a Ruthless CancerGlioblastoma (GBM) is one of the deadliest cancers, with a five-year survival rate of just 6.9% and an average survival of eight months. It impacts cognition, mood, and independence, placing emotional and financial burdens on patients and families. With only a handful of FDA-approved treatments, GBM remains a significant challenge, but innovations like Shuttle Pharma’s Ropidoxuridine offer hope for better outcomes.&nbsp;Pipeline Overview and Flagship DrugShuttle Pharma’s pipeline includes:<ul><li>Ropidoxuridine (IPdR): Their flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes. The drug has received an Orphan Drug Designation, ensuring market exclusivity upon approval (3). Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.</li><li>SP-2-225: A preclinical HDAC6 inhibitor targeting immune activation post-RT. HDAC6 inhibitors are emerging as a transformative class of drugs with the potential to improve tumor recognition by the immune system (4). This drug could have broad applications combined with radiation therapy and other immune therapies, addressing a large oncology market.</li><li>SP-1-303: Another preclinical asset targeting estrogen receptor-positive breast cancers, a subtype that represents a significant portion of all breast cancer diagnoses. Its unique mechanism of action and potential synergy with current hormonal treatments create substantial commercial potential.</li></ul><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shuttle_pharma_pipeline_8164d4c4cb.png" alt="shuttle-pharma-pipeline.png">&nbsp;Market Potential for Ropidoxuridine and Other CandidatesRadiation sensitizers represent a multi-billion-dollar opportunity. The global radiation therapy market is projected to grow significantly, reaching $14.18 billion by 2028 (2). Approximately 50% of all cancer patients undergo radiation therapy, amounting to a substantial number of patients annually in the US alone (1). A significant portion of these patients are treated with curative intent, offering a target market potentially worth billions for sensitizing agents.With glioblastoma as the initial target, Shuttle’s technology could eventually expand into other cancer types where radiation is a core treatment modality, such as lung, breast, and gastrointestinal cancers. By reducing radiation toxicity and improving tumor control, Ropidoxuridine could become an essential adjunct to standard cancer care.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/global_radiation_therapy_market_graph_9d83a88dbe.jpeg" alt="global-radiation-therapy-market-graph.jpeg">Simple Mechanism of Action and Proven SafetyRopidoxuridine acts as a prodrug, metabolized into IUdR upon ingestion. IUdR incorporates into cancer DNA, enhancing RT-induced DNA damage while sparing healthy cells.In layman’s terms, Ropidoxuridine is like a “homing beacon” for radiation therapy, guiding the radiation to attack cancer cells while avoiding healthy tissues. This straightforward and targeted approach significantly increases the likelihood of clinical success compared to more complex therapies.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/how_does_ropidoxuridine_work_17eaa74e99.png" alt="how-does-ropidoxuridine-work.png">Comparative Analysis: Valuation vs. PeersBiotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million (5). Currently valued at approximately $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the upside potential.&nbsp;Similar Stage Comparisons: Phase 2 Enrollment<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/leap-therapeutics">Leap Therapeutics (NASDAQ: LPTX)</a><ul><li>Market Cap: Approximately $82 million</li><li>Focus: Antibody-based therapies targeting immune modulation in cancer.</li><li>Pipeline: DKN-01, currently in Phase 2 for gastric and gynecologic cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">(4)</a>.</li><li>Comparison Insight: Leap Therapeutics commands a valuation over 20x that of Shuttle Pharma, underscoring the latter’s deep undervaluation relative to its stage of development.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/nextcure">NextCure (NASDAQ: NXTC)</a><ul><li>Market Cap: Approximately $23 million</li><li>Focus: Immune therapies targeting novel tumor-specific antigens.</li><li>Pipeline: NC318, currently in Phase 2 trials for advanced solid tumors.</li><li>Comparison Insight: NextCure reflects the market’s optimism for immune-oncology therapies in Phase 2 trials.</li><li>Demonstrated Efficacy Comparisons: Post-Positive Phase 2</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/kura-oncology">Kura Oncology (NASDAQ: KURA)</a><ul><li>Market Cap: Approximately $620 million</li><li>Focus: Precision oncology for genetically defined cancers.</li><li>Pipeline: Tipifarnib, demonstrating efficacy in Phase 2 for HRAS-mutant cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">(6)</a>.</li><li>Comparison Insight: Kura highlights the potential valuation growth when efficacy is shown in Phase 2 for a targeted therapeutic.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/adicet-bio">Adicet Bio (NASDAQ: ACET)</a><ul><li>Market Cap: Approximately $76 million</li><li>Focus: Allogeneic gamma-delta T cell therapies for oncology.</li><li>Pipeline: ADI-001, demonstrating Phase 2 efficacy in B-cell lymphomas.</li><li>Comparison Insight: Adicet underscores how valuation grows post-efficacy, aligning with Shuttle Pharma’s potential trajectory.</li></ul>&nbsp;An Accomplished Team Backed by Prestigious InstitutionsShuttle Pharma’s leadership is grounded in expertise, with key team members boasting extensive experience in oncology drug development:<ul><li>Dr. Anatoly Dritschilo: CEO and co-founder, a globally recognized radiation oncology expert with over 40 years of experience. Dr. Dritschilo has published extensively on radiation therapy and drug discovery and is an innovator in developing strategies for radiosensitization and therapeutic resistance.</li><li>Dr. Tyvin Rich: Medical Director with experience at MD Anderson and Harvard, specializing in radiation sensitizers.</li><li>Dr. Mira Jung: Scientific Director and co-founder, a professor of Radiation Medicine at Georgetown University.</li></ul>The rest of the team comprises an impressive roster of PhDs, MDs, and industry veterans with decades of combined experience developing oncology therapies and navigating FDA regulatory pathways.Strong Insider Ownership and Shareholder AlignmentWith 28.3% insider ownership, including a significant investment from the CEO, Shuttle Pharma’s management is deeply aligned with shareholder interests. This rare level of insider ownership reflects confidence in the company’s potential. High insider ownership ensures that decision-makers have “skin in the game,” aligning their financial interests with investors and creating trust in long-term value creation. Additionally, if clinical data supports efficacy, the small public float (2.9 million shares) positions the stock for dramatic price appreciation.Conclusion: The Undervalued Biotech to WatchShuttle Pharma’s small float, strong leadership, and groundbreaking focus on radiation sensitizers position it as one of the most undervalued opportunities in biotech. With a Phase 2 trial underway and a massive addressable market, Shuttle could redefine cancer treatment while offering exponential upside for investors. Comparisons to higher-valued peers only underscore the gap—and the potential for rapid revaluation if results prove successful.Shuttle Pharma’s other drug candidates, including SP-2-225 and SP-1-303, offer compelling bonuses for investors. These unique yet complementary assets could potentially expand Shuttle’s market reach in oncology. Additionally, the company’s diagnostic tools present a unique opportunity: they often have more streamlined FDA approval processes than therapeutics and could potentially be spun off as a standalone business, unlocking significant shareholder value.References<ol><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/basics.html">American Cancer Society: Radiation Therapy Overview</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.researchandmarkets.com/report/radiation-therapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kpswcb&amp;utm_campaign=1977747+-+Global+Radiation+Therapy+Market+with+Focus+on+LINAC%2c+2024+Market+Report%3a+A+%2414.18+Billion+Market+in+2028%2c+Registering+a+Projected+CAGR+of+6.75%25+During+2024-2028&amp;utm_exec=carimspi">Global Radiation Therapy Market Report</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=519016">FDA Orphan Drug Designation List</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">Leap Therapeutics Corporate Pipeline</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/">Biotech Valuation Trends</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">Kura Oncology: Pipeline</a></li></ol>This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

Equity

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH</a>), a rising force in cancer treatment innovation, has experienced a notable boost in its stock price following a recent wave of positive developments. Shares of Shuttle Pharma's stock surged 63% in after-hours trading Monday as news of these milestones spread. On Tuesday, Shuttle Pharmaceuticals' stock rose as much as 69%, reaching a high of $2.25.&nbsp;Also Read:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">The 2024 Space Race is All Systems Go—As Space Stocks Throttle Up, Our Top Pick Has Already Rocketed 588% Higher in Just Three Months</a>&nbsp;The pharmaceutical company, dedicated to enhancing the efficacy of radiation therapy for cancer patients, updated investors on significant progress in its Phase 2 clinical trial of Ropidoxuridine, a promising radiation sensitizer aimed at improving outcomes for glioblastoma patients. Additionally, the company closed a $4.5 million public offering, ensuring robust funding for its ongoing and future projects.Although the company’s shares had experienced a downward trend earlier this year, investors appeared encouraged by the updates on both its clinical advancements and financial position.Shuttle Pharma’s CEO, Dr. Anatoly Dritschilo,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29260452/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma">commented on the developments</a>, stating:“We have successfully engaged all six of the planned clinical trial site locations to administer the Phase 2 clinical trial of ropidoxuridine. All six locations are nationally recognized cancer centers that are most likely to treat IDH wild-type, methylation negative glioblastoma patients, the target of the clinical trial.”<h3>Clinical Trial Progress and Patient Impact</h3>Shuttle Pharmaceuticals’ Phase 2 clinical trial for Ropidoxuridine is focused on patients with IDH wild-type, methylation-negative glioblastoma—a particularly aggressive form of brain cancer that currently has no cure. While radiation therapy remains the standard treatment for these patients, more than half survive less than 12 months following diagnosis, underscoring the urgent need for more effective therapies.With the trial now actively&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29260452/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma">enrolling patients</a>, Shuttle is running its study across six major cancer centers, including Georgetown University Medical Center and UNC Medical Center, and previously engaged facilities such as UVA Cancer Center and John Theurer Cancer Center. The trial aims to determine the optimal dosing of Ropidoxuridine, with patients divided into two dosage groups. Upon determining the optimal dose, the trial will proceed with an additional 14 patients to assess survival outcomes.Dr. Dritschilo emphasized the impact of this work on the broader cancer community, stating:“The results of this trial will be important as we look for effective radiation sensitizers to increase cancer cure rates and improve patients’ quality of life.”On Tuesday, the company announced the&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29274680/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma">successful dosing</a> of the first three patients in its Ropidoxuridine Phase 2 clinical trial. Shuttle Pharma expects the clinical trial to reach completion within 18 to 24 months, potentially offering a lifeline to thousands of glioblastoma patients who currently face limited treatment options.“The initiation of patient dosing in our Phase 2 trial of Ropidoxuridine for the treatment of patients with glioblastoma is a significant milestone for both Shuttle Pharma and the thousands of patients with brain tumors who currently lack effective therapies,”&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29274680/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma">commented Dr. Dritschilo</a>.&nbsp;Also Read:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">The 2024 Space Race is All Systems Go—As Space Stocks Throttle Up, Our Top Pick Has Already Rocketed 588% Higher in Just Three Months</a>&nbsp;<h3>Strengthened Financial Position</h3>Alongside clinical advancements, Shuttle Pharmaceuticals is working hard to fortify its financial position. Yesterday, Shuttle Pharma&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29287769/shuttle-pharmaceuticals-holdings-inc-announces-pricing-of-45-million-public-offering-priced-at-the-market-under-nasdaq-rules">announced the pricing</a> of a new public offering with a health-care-focused institutional investor for the sale of 2,950,820 common shares and an equal number of warrants to purchase additional shares. The offering, priced at $1.525 per share, includes warrants exercisable at $1.40 per share, with a five-year expiration window. Shuttle Pharma expects to receive gross proceeds of roughly $4.5 million from the offering.The financing, led by A.G.P./Alliance Global Partners with support from Boustead Securities, provides critical funding to advance Shuttle Pharma’s clinical programs and provide the company with additional working capital. Shuttle intends to allocate part of these proceeds to the Phase 2 Ropidoxuridine trial, covering essential costs such as payments to its clinical research organization, Theradex Systems. The rest of the funds will support general corporate expenses, ensuring that Shuttle remains financially equipped to continue its ambitious research and development plans.<h3>&nbsp;</h3><h3>Shuttle Pharma Pays Off Convertible Note</h3>Beyond securing new capital, Shuttle Pharmaceuticals has also worked to improve its balance sheet by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29283786/shuttle-pharma-pays-off-senior-secured-convertible-note">paying off</a> its senior secured convertible note, which had a principal balance of $4.3 million as of January 2023. Through a series of payments and share issuances, the company retired this debt, a move that grants it greater flexibility in advancing its clinical programs without the burden of this financial obligation.Dr. Dritschilo, who has personally invested in the company’s recent financing efforts, sees the debt elimination as a pivotal step in Shuttle Pharma's journey.“The elimination of the convertible note along with obtaining the bridge funding provides us with added flexibility to advance our ongoing Phase 2 clinical trial for the treatment of patients with glioblastoma,”&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/story/news/29283786/shuttle-pharma-pays-off-senior-secured-convertible-note">noted Dr. Dritschilo</a>.His comment underscores the company’s determination to prioritize clinical innovation and patient-centred results over short-term financial constraints.<h3>&nbsp;</h3><h3>Growing Opportunity in Radiation Therapy</h3>Shuttle Pharmaceuticals’ work with Ropidoxuridine highlights a promising opportunity in the field of radiation therapy. Approximately 800,000 cancer patients in the US receive radiation therapy each year, with half treated with curative intent. By enhancing radiation’s effectiveness with sensitizers like Ropidoxuridine, Shuttle Pharma aims to tap into an expanding market projected to grow by 22% over the next five years. The company holds an Orphan Drug Designation from the FDA for Ropidoxuridine, which could offer exclusive marketing rights if the drug achieves regulatory approval, further solidifying Shuttle’s position in this niche market.In anticipation of these potential benefits, Shuttle is maintaining momentum with plans to continue expanding its research into other types of radiation sensitizers and diagnostics. The company has highlighted the importance of personalized approaches, including biomarker-driven diagnostics, to increase the precision and effectiveness of radiation therapy for various cancers.<h3>&nbsp;</h3><h3>Investor Confidence and Future Outlook</h3>While Shuttle Pharmaceuticals remains a smaller player within the broader pharmaceutical industry, the recent surge in its stock price reflects growing investor confidence in its mission and progress. The combination of substantial clinical updates and enhanced financial resources strengthens the company’s potential to make a meaningful impact on the treatment of glioblastoma and possibly other cancers in the future.As Shuttle navigates the complex path of clinical research and development, its progress will be closely watched by both the oncology community and the financial market. For now, the company’s recent milestones offer promising steps forward, providing hope for patients and reinforcing its commitment to transforming radiation therapy’s role in cancer treatment.<h3>&nbsp;</h3><h3>Shuttle Pharmaceuticals (NASDAQ: SHPH) Stock Price Action and Chart</h3>Shares of&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/stocks/quotes/SHPH/overview">Shuttle Pharma (NASDAQ: SHPH)</a> stock closed Wednesday's trading session at $1.80 per share, finishing the day even.Since hitting a low on October 9, 2024, SHPH stock has risen as much as&nbsp;118%.YTD, SHPH stock is down&nbsp;55.45%.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_02_at_2_42_01_AM_fcf7da6965.png" alt="Screenshot 2024-11-02 at 2.42.01 AM.png">&nbsp;Read Next:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">The 2024 Space Race is All Systems Go—As Space Stocks Throttle Up, Our Top Pick Has Already Rocketed 588% Higher in Just Three Months</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News

Shares of Shuttle Pharmaceuticals are on the rise following a string of recent developments, including positive updates on its Phase 2 clinical trial, a new $4.5 million public offering and the paying off of a convertible note.

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Gaithersburg, MD.

Current Price	$1.06
Prev Close	$1.18
Open	$1.13
Dividend Yield	0.00%
50-Day Moving Average	$1.72
Beta	0.15
Avg. Volume	7.73M
PE Ratio	-0.05

52-Week High	$16.90
52-Week Low	$1.00
Market Capitalization	$3.45M
EPS (Annual)	-$82.60
Price to Book	0.94
Revenue Per Employee	$0.00

SHPH
Shuttle Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SHPH News

SHPHShuttle Pharmaceuticals Holdings Inc